Mutual of America Capital Management LLC Sells 539 Shares of Catalent, Inc. (NYSE:CTLT)

Mutual of America Capital Management LLC decreased its position in shares of Catalent, Inc. (NYSE:CTLT) by 2.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,257 shares of the company’s stock after selling 539 shares during the period. Mutual of America Capital Management LLC’s holdings in Catalent were worth $1,348,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. O Shaughnessy Asset Management LLC bought a new stake in shares of Catalent in the first quarter valued at approximately $214,000. California State Teachers Retirement System lifted its position in shares of Catalent by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 284,815 shares of the company’s stock valued at $16,078,000 after acquiring an additional 1,149 shares during the period. National Wealth Management Group LLC bought a new position in shares of Catalent in the first quarter worth $359,000. Swedbank AB bought a new position in shares of Catalent in the first quarter worth $1,659,000. Finally, Redwood Grove Capital LLC raised its stake in Catalent by 23.0% in the first quarter. Redwood Grove Capital LLC now owns 308,156 shares of the company’s stock valued at $17,395,000 after purchasing an additional 57,600 shares in the last quarter.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Catalent Price Performance

Shares of NYSE:CTLT opened at $61.24 on Tuesday. The firm has a 50 day simple moving average of $59.81 and a 200 day simple moving average of $58.32. The company has a market cap of $11.12 billion, a price-to-earnings ratio of -27.10, a PEG ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a one year low of $36.74 and a one year high of $61.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business earned ($0.10) EPS. Research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CTLT. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus price target of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.